Lunan New Media   Duan Yuqing   23th December 2019

On 21th December 2019, the marketing meeting of the anticoagulant Mailuochang® Argatroban Injection of Lunan Pharmaceutical was held in Jinan, Shandong province. More than 200 experts and professors were present to discuss the application prospect of argatroban in anticoagulation field. 

Lunan Pharmaceutical’s Argatroban Injection, with the product’s name "Mai Luo Chang" (Chinese name: 麦洛畅),  received approval of two indications for acute cerebral infarction and chronic atherosclerosis. As an anticoagulant, Argatroban Injection has been listed in the national medical insurance catalogue in China.

Argatroban Injection, as a direct thrombin inhibitor, can go deep into the internal blood clots, effectively restrain the thrombin combined with fibrin, it has unique advantages: quick effect, short time in functioning, low bleeding tendency.

Lunan Pharmaceutical’s antiplatelet drug Tirofiban Hydrochloride Injection, with the product’s name "Heng Kang "(Chinese name:恒康) has been widely used in stroke patients, and the marketed Argatroban Injection will contribute a lot in anticoagulation field.

Lunan Pharmaceutical general manager assistant Meng Fanqiang, Zhu Yanhua attended.